Grant: CIHR Fellowship
McGill University
$275,000.00
Development and validation of clinical prediction rules of quality of life in head and neck cancer
EF 2011-12
Résumé
Head and neck cancers severely impair quality of life (QOL) as they affect breathing, eating, speaking, and physical appearance. Up to 50% of patients with these cancers suffer from depression, which is the highest rate among oncology patients. Regular evaluations of QOL and depression are essential to correctly identify and treat these issues, as well as to optimize treatments. However, routine assessment is not common due to the time and resources required. In head and neck cancer, there is no clinical prediction score for QOL and depression, although predictions scores can simplify and increase diagnostic and prognostic assessments. Moreover, HPV infection is recognized as a favourable prognostic factor in head and neck cancer, and its role in QOL and depression has never been evaluated
Our objectives are to identify predictors of QOL and depression in head and neck cancer, to evaluate the role of HPV as a prognostic factor, and to develop and validate a clinical prediction score of QOL and depression.
This study will take place at Notre-Dame Hospital, where the largest number of head and neck cancer patients are treated in Quebec. The first step will identify the most significant predictive factors of QOL and depression, including HPV. The second step is the creation of prediction scores using the most significant prognostic factors of QOL. The third step is the prospective validation of these scores over 24 months.
This is the first study to develop clinical scores to predict QOL and depression in head and neck cancer. This is also the first study to evaluate the role of HPV in QOL and depression. Current research and clinical practice does not routinely evaluate QOL and depression in head and neck cancer. This issue will be addressed by creating a simple rule that can eventually be implemented in clinical practice after proper validation. We hope that this will increase routine evaluation of QOL and depression in research and in clinical practice.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
258367
Name
Moubayed Sami P
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Health Research Training B - HP
Projecttitle
Development and validation of clinical prediction rules of quality of life in head and neck cancer
Programtype2
Fellowship Programs
Orgnameinp2
McGill University
Cihramount2
$275,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Biomarkers; Clinical Prediction Rule; Depression; Head And Neck Cancer; Hpv; Patient-Reported Outcomes; Prediction Score; Predictive Factors; Prognostic Factors; Quality Of Life
Abstract
Head and neck cancers severely impair quality of life (QOL) as they affect breathing, eating, speaking, and physical appearance. Up to 50% of patients with these cancers suffer from depression, which is the highest rate among oncology patients. Regular evaluations of QOL and depression are essential to correctly identify and treat these issues, as well as to optimize treatments. However, routine assessment is not common due to the time and resources required. In head and neck cancer, there is no clinical prediction score for QOL and depression, although predictions scores can simplify and increase diagnostic and prognostic assessments. Moreover, HPV infection is recognized as a favourable prognostic factor in head and neck cancer, and its role in QOL and depression has never been evaluated
Our objectives are to identify predictors of QOL and depression in head and neck cancer, to evaluate the role of HPV as a prognostic factor, and to develop and validate a clinical prediction score of QOL and depression.
This study will take place at Notre-Dame Hospital, where the largest number of head and neck cancer patients are treated in Quebec. The first step will identify the most significant predictive factors of QOL and depression, including HPV. The second step is the creation of prediction scores using the most significant prognostic factors of QOL. The third step is the prospective validation of these scores over 24 months.
This is the first study to develop clinical scores to predict QOL and depression in head and neck cancer. This is also the first study to evaluate the role of HPV in QOL and depression. Current research and clinical practice does not routinely evaluate QOL and depression in head and neck cancer. This issue will be addressed by creating a simple rule that can eventually be implemented in clinical practice after proper validation. We hope that this will increase routine evaluation of QOL and depression in research and in clinical practice.
Competitiondate
201202
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Moubayed, Sami P
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $275,000~ $0~